Liver Reference Set-Rapid-Application: Nilsson Glycobond (2018)

Abbreviated Name
Liver Rapid Ref Set App: Nilsson (2018)
Lead Investigator
Nilsson, Anki — Glycobond
Coordinating Investigator
Zheng, Yingye — Fred Hutchinson Cancer Center
Involved Investigators

Abstract

The markers that will be tested in the reference set are the following: S2-bound AGP, AFP, AFP-L3 and DCP (PIVKA II). AFP-L3 ELISA is not sensitive for low AFP samples and the µTASWako analysis system for AFP-L3 requires a larger sample volume (1 ml serum). We therefore have to exclude the AFP-L3 analysis from the request.

Aims

The markers that will be tested in the reference set are the following: S2-bound AGP, AFP, AFP-L3 and DCP (PIVKA II). AFP-L3 ELISA is not sensitive for low AFP samples and the µTASWako analysis system for AFP-L3 requires a larger sample volume (1 ml serum). We therefore have to exclude the AFP-L3 analysis from the request.

Analytic Method

Analyzed by DMCC

Comments

No comments available.

Outcome

The HepaCheC biomarker demonstrated some discrimination between early-stage HCC cases (N=50) and cirrhotic controls (N=50) in the EDRN Liver Rapid Reference Set. The observed AUC was 0.59 (95% CI 0.47; 0.71) and the observed sensitivity at 90% specificity was 0.28 (95% CI 0.06; 0.4). The combination of HepaCheC and log-transformed AFP, which demonstrated: AUC = 0.80 (95% CI 0.71; 0.88) and sensitivity at 90% specificity = 0.58 (95% CI 0.36; 0.76), did not improve on AFP alone, which demonstrated: AUC = 0.80 (95% CI 0.71; 0.88) and sensitivity at 90% specificity = 0.58 (95% CI 0.4; 0.76). Subsequent analysis on subsets with Alcoholic Liver Disease (15 cases; 15 controls) and Hepatitis C Virus (27 cases; 32 controls) gave qualitatively similar results.

Secure Outcome

No secure outcome available.

Publications

  • No publications available at this time for this protocol.

Biomarkers

Data Collections

  • No data collections available at this time for this protocol.
 Team Project
Start Date
May 25 2018
Estimated Finish Date
Sep 25 2018
Finish Date
Jan 15 2019
Protocol ID
446
Protocol Type
Reference Set
Fields of Research
  • Proteomics
Collaborative Group
G.I. and Other Associated Cancers Research Group
Cancer Types
  • Liver cell carcinoma
Phased Status
1

Associated Forms